Science Session News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Milestone Pharmaceuticals Inc. recently announced positive Phase 2 data that show etripamil nasal spray resulted in rapid and statistically superior ventricular rate reduction and improved symptom-relief in patients with atrial fibrillation with rapid ventricular rate (AFib-RVR) compared to placebo. The findings were presented during the American Heart Association Scientific Sessions 2023, held recently in Philadephia, PA.

City ofUnited kingdomUnited statesOlmsted countyA john cammDavid bharuchaCardiology clinical academic groupMilestone pharmaceuticals incClinical sciences research instituteDuring the american heart association scientific sessionsMilestone pharmaceuticalsAmerican heart association council on epidemiologyGeorge university of londonPrevention statistics committeeA report from the american heart associationDrug administration